Palforzia (peanut allergen oral immunotherapy) prior authorization
Defines UnitedHealthcare prior authorization/notification criteria for initial and reauthorization coverage of Palforzia for patients with confirmed peanut allergy, and who is affected (patients and prescribing providers).
Updated age range based on update to prescribing information.
Added mandate language during annual review.
Annual review with updated references.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.